In pursuit of new anti-angiogenic therapies for cancer treatment

Front Biosci (Landmark Ed). 2011 Jan 1;16:803-14. doi: 10.2741/3721.

Abstract

Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of anti-angiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Bevacizumab
  • Drug Resistance, Neoplasm
  • Humans
  • Indoles / therapeutic use
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic / drug therapy*
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Oligonucleotides
  • Phenylurea Compounds
  • Pyridines / therapeutic use
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Quinazolines / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins / therapeutic use
  • Sorafenib
  • Sulfonamides / therapeutic use
  • Sunitinib
  • Tumor Microenvironment

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Oligonucleotides
  • Phenylurea Compounds
  • Pyridines
  • Pyrimidines
  • Pyrroles
  • Quinazolines
  • Recombinant Fusion Proteins
  • Sulfonamides
  • aflibercept
  • Niacinamide
  • Bevacizumab
  • pazopanib
  • Sorafenib
  • Receptors, Vascular Endothelial Growth Factor
  • imetelstat
  • cediranib
  • Sunitinib